European Commission OKs Vyvgart for AChR-positive Generalized MG
The European Commission has approved Vyvgart (efgartigimod) as an add-on to standard treatment for adults with generalized myasthenia…
Articles by Marisa Wexler, MS
Adding IV Immunoglobin to Steroids Better Treats Children with OMG
A combination of glucocorticoids and intravenous immunoglobulin (IVIG) is more effective at normalizing immune responses and easing disease symptoms…
China Agrees to Review Efgartigimod for Generalized MG
Zai Lab’s application seeking approval of efgartigimod in China to treat adults with generalized myasthenia gravis (gMG)…
FDA Places Partial Hold on Phase 3 Clinical Trials of Tolebrutinib
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Phase 3 trials that are testing…
Lymphoplasma Exchange Can Ease MG Symptoms in Flares, Study Finds
Lymphoplasma exchange — a procedure that involves exchanging a patient’s plasma and also removing certain immune cells from the bloodstream…
Ultomiris Is Approved in the US for Treating AChR-positive gMG
The long-acting complement inhibitor Ultomiris (ravulizumab-cwvz) has been approved by the U.S. Food and Drug Administration (FDA) to treat most…
Europe Awaits Proposed New Framework for Sharing Health Data
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
#AAN2022 – Clinical Benefits of Ultomiris Sustained for Over a Year
Treatment with Ultomiris (ravulizumab-cwvz) eased symptoms of generalized myasthenia gravis (gMG) for more than a year, according to new…
Study Details Clinical Course of Anti-MuSK-positive MG
Many people with myasthenia gravis (MG) caused by antibodies against MuSK initially present with eye-related symptoms, which soon affect…
Soliris Outperforms Rituximab at Controlling MG Symptoms: Study
Soliris (eculizumab) is better than rituximab at controlling myasthenia gravis (MG) symptoms over a two-year period, according to…